Salvia, traditionally, S. divinorum has been ingested by chewing fresh leaves or by drinking their extracted juices. The dried leaves of S. divinorum can also be smoked in rolled cigarettes or pipes or vaporized and inhaled.
Although information about S. divinorum is limited, its use may be driven in part by drug-related videos and information on Internet sites. Because of the nature of the drug’s effects—brief hallucinogenic experiences that mimic psychosis—it is more likely to be used in individual experimentation than as a social or party drug.
The main active ingredient in salvia, salvinorin A, is a potent activator of nerve cell targets called kappa opioid receptors. (These receptors differ from the receptors activated by commonly known opioid drugs such as heroin and morphine.) Although salvia is generally considered a hallucinogen, it does not act at serotonin receptors that are activated by other hallucinogens like LSD or psilocybin, and its effects are reported by experienced users to be different from those drugs.
Subjective effects of S. divinorum use have been described as intense but short-lived, appearing in less than 1 minute and lasting less than 30 minutes. They include psychedelic-like changes in visual perception, mood and body sensations, emotional swings, feelings of detachment, and a highly modified perception of external reality and the self, leading to a decreased ability to interact with one’s surroundings. This last effect has prompted concern about the dangers of driving under the influence of salvinorin.
What Are the Other Health Effects of Salvia?
The psychological or physical health effects of S. divinorum use have not been investigated systematically, and consequences of long-term use are not known. Experiments in rodents demonstrated deleterious effects of salvinorin A on learning and memory, but there is little evidence of salvia causing dependence or long-term psychiatric problems in humans.
National Institute on Drug Abuse
Recreational use and legal status in …
S. Djezzar1, L. de Haro2, M.A. Courné3, R. Garnier1,4, The Addictovigilance and Toxicovigilance Networks1. 1Centre of Evaluation, Information on …
Drug Identification Guide
CDC Addiction Info
CDC Overdose Stats
CDC Substance Treatment
Whitehouse Drug-Free Communities
Samhsa Workplace Programs
Federal Register Codification